This DOD-funded project seeks to find vaccine candidates against pathogens that cause chronic biofilm infections in returning soldiers including Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
This NIH-NIAID project is elucidating the host response to find out how Staphylococcus aureus is able manipulate the host immune response and avoid clearance to progress from an acute infection to one that is chronic and mediated by biofilms. We are also modulating this ineffective immune response to enable the host to clear staphylococcal infections.
The eukaryote fungus, C. albicans, and the prokaryote bacteria S. aureus interact in a biofilm mode of growth to promote systemic staphylococcal infection through physical interactions and modulation of virulence factor expression. Our research funded by the National Institutes of Health NIDCR in collaboration with Dr. Vincent Bruno at the Institute for Genomic Sciences, is directed at understanding this physical interaction as well as the proteomic changes when these two microbial species interact.
Biofilms are notoriously difficult to diagnose since the small nidus of infection is often missed when tissue is extracted for culture. It is important to discern whether the infection is a localized biofilm or a free-floating planktonic infection since the treatment modalities for these two forms of infections are significantly different. In particular, biofilm infections, in converse to the planktonic modes of infection, are resistant to clearance by antimicrobial agents. In order to better diagnose biofilm infections, our laboratory has developed a rapid biofilm lateral flow immunoassay that detects host antibodies generated against biofilm specific proteins in the sera as well as an in vivo diagnostic agent that is based upon labelled antibodies against biofilm specific antigens that can be injected into the host and localize at areas of biofilm infection.
The purpose of this project is to demonstrate that C. difficile forms a biofilm in clinical cases of pseudomembranous colitis. In addition, once we identify antigens that are recognized by the host immune response in vivo through an immunoproteomic approach, we will use these proteins as vaccine candidates for the prevention of gastrointestinal disease by C. difficile.
Advanced TB infections are remarkably hard to cure due to the presence of the microbe in a granuloma derived from host and pathogen factors. Although this form of infection should be considered a biofilm infection, nearly all of the vaccine and proteomic/transcriptomic/phenotypic studies have used the free floating or planktonic mode of growth model. Therefore, our goal is to analyze the host response and proteomic nature of M. tuberculosis in a biofilm mode of growth.
Principal Investigator
Lead Research Specialist
smajumdar1@umaryland.edu
“Mark was a leading international biofilm researcher of exceptional productivity,” said Patrik Bavoil, PhD, professor and chair of the UMSOD Department of Microbial Pathogenesis. “He was a prolific author and a very generous colleague. His level of commitment to his research and students was remarkable. And his personality was such that once you met Mark, you didn’t forget him.”
Copyright © 2024 Ernst Laboratory - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.